Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Scheffold, Felix Seyfried, Lüder Meyer, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Stephan Stilgenbauer, Billy Michael Chelliah Jebaraj

Blood (2022) 140 (Supplement 1): 3139–3141.

https://doi.org/10.1182/blood-2022-159427

Published: 2022

Journal Articles

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 487–488.

https://doi.org/10.1182/blood-2022-168166

Published: 2022

Journal Articles

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Eugen Tausch, Viktor Ljungström, Andreas Agathangelidis, Marc Zapatka, Lydia Scarfò, Billy Michael Chelliah Jebaraj, Deyan Y. Yosifov, Annika Müller, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Paolo Ghia, Richard Rosenquist, Stephan Stilgenbauer

Blood (2022) 139 (22): 3340–3344.

https://doi.org/10.1182/blood.2021014550

Published: 2022

Includes: Supplemental data

Journal Articles

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M. Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A. Fox, Klaus-Michael Debatin, Lüder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer

Blood (2022) 139 (6): 859–875.

https://doi.org/10.1182/blood.2021011516

Published: 2022

Includes: Supplemental data

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Daniela Steinbrecher, PhD, Felix Seyfried, MD, Eugen Tausch, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Christof Schneider, MD

Blood (2019) 134 (Supplement_1): 1507.

https://doi.org/10.1182/blood-2019-127931

Published: 2019

Journal Articles

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, André Lechel, Sarah-Fee Katz, PhD, Eugen Tausch, Johannes Bloehdorn, MD, Daniela Steinbrecher, PhD, Vanni Torresi, Christof Schneider, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Lenhard Rudolph, Stephan Stilgenbauer

Blood (2019) 134 (Supplement_1): 1732.

https://doi.org/10.1182/blood-2019-126878

Published: 2019

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, Eugen Tausch, MD, Judith A. Fox, PhD, Pietro Taverna, PhD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2018-99-116664

Published: 2018

Journal Articles

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Johannes Bloehdorn, MD, Julia Krzykalla, MSc, Billy Michael Chelliah Jebaraj, PhD, Karlheinz Holzmann, Dr. rer. nat., Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kathryn Humphrey, Michael Wenger, Eugen Tausch, MD, Christof Schneider, MD, Lars Bullinger, MD, Kirsten Fischer, MD, Michael Hallek, MD, Daniel Mertens, Axel Benner, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2018-99-116937

Published: 2018

Journal Articles

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Daniela Steinbrecher, MSc, Felix Seyfried, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Christof Schneider, MD

Blood (2018) 132 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2018-99-115845

Published: 2018

Journal Articles

PI3K-δ Inhibition Influences T-Cell Populations and Anti-Tumoral Immune Function in Preclinical Models

Annika Scheffold, Bola S Hanna, PhD, Philipp Roeßner, Yasmin Demerdash, Billy Michael Chelliah Jebaraj, PhD, Peter Lichter, PhD, Stephan Stilgenbauer, MD PhD, Martina Seiffert

Blood (2017) 130 (Supplement 1): 2998.

https://doi.org/10.1182/blood.V130.Suppl_1.2998.2998

Published: 2017

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Eugen Tausch, MD, Sven Estenfelder, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1708.

https://doi.org/10.1182/blood.V130.Suppl_1.1708.1708

Published: 2017

Journal Articles

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Anella Yahiaoui, Anna Dolnik, PhD, Tamara Jacqueline Blaette, M.sc., Lars Bullinger, MD, Christof Schneider, MD, Daniel Mertens, PhD, Veerendra Munugalavadla, Shih-Shih Chen, PhD, Nicholas Chiorazzi, MD, Stacey Tannheimer, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 190.

https://doi.org/10.1182/blood.V128.22.190.190

Published: 2016

Journal Articles

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Paolo Ghia, Viktor Ljungström, Eugen Tausch, Andreas Agathangelidis, Annika Scheffold, Lydia Scarfo, Billy Michael Chelliah Jebaraj, Carolyn J. Owen, MD MDes(UK), FRCPC, Jacqueline C. Barrientos, MD, Marc Zapatka, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Yeonhee Kim, Ronald L. Dubowy, Lyndah K. Dreiling, Richard Rosenquist, Stephan Stilgenbauer

Blood (2016) 128 (22): 2770.

https://doi.org/10.1182/blood.V128.22.2770.2770

Published: 2016

Journal Articles

Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Annika Scheffold, M.Sc., Billy Michael Chelliah Jebaraj, PhD, André Lechel, PhD, Sarah-Fee Katz, PhD, Daniela Steinbrecher, M.Sc., Vanni Torresi, M.Sc., Christof Schneider, MD, Daniel Mertens, PhD, Hartmut Döhner, MD, Karl-Lenhard Rudolph, MD, Stephan Stilgenbauer, MD

Blood (2015) 126 (23): 1724.

https://doi.org/10.1182/blood.V126.23.1724.1724

Published: 2015

Journal Articles

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Annika Scheffold, MSc, Billy Michael Chelliah Jebaraj, PhD, Eugen Tausch, MD, Sebastian Boettcher, MD, Matthias Ritgen, Donald Bunjes, MD, Matthias Zeis, MD, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MDPhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD PhD, Norbert Schmitz, MD PhD, Hartmut Doehner, MD, Peter Dreger, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1951.

https://doi.org/10.1182/blood.V124.21.1951.1951

Published: 2014

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

Telomere length in mantle cell lymphoma

Billy Michael Chelliah Jebaraj, Dirk Kienle, André Lechel, Daniel Mertens, Maria Heuberger, German Ott, Andreas Rosenwald, Thomas F. E. Barth, Peter Möller, Thorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer

Blood (2013) 121 (7): 1184–1187.

https://doi.org/10.1182/blood-2012-08-452649

Published: 2013

Includes: Supplemental data

NARROW

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

PI3K-δ Inhibition Influences T-Cell Populations and Anti-Tumoral Immune Function in Preclinical Models

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Telomere length in mantle cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only